Understanding DIO3 Intracellular Trafficking in Ovarian Cancer

Recent research identifies DIO3 intracellular trafficking as a critical factor in high-grade serous ovarian cancer (HGSOC). Type 3 iodothyronine deiodinase (DIO3) is a membrane-associated enzyme that inactivates thyroid hormones. Since thyroid hormones typically act as tumor suppressors, DIO3 activity promotes cancer cell survival. By continuously recycling between the plasma membrane and endosomes, DIO3 maintains its functional stability within the tumor environment.

The Role of Sorting Nexins in DIO3 Intracellular Trafficking

Scientists have now identified sorting nexins SNX2 and SNX6 as essential components of this machinery. These proteins facilitate the movement of DIO3 through different cellular stations. For instance, SNX6 drives the progression of the enzyme through the Golgi and endosomal compartments. Meanwhile, SNX2 directs the recycling of DIO3 back to the plasma membrane using RAB11-positive vesicles. This continuous routing ensures that the enzyme remains active, thereby supporting the progression of ovarian cancer cells.

Clinical Implications and Therapeutic Vulnerabilities

The study highlights that disrupting these specific trafficking pathways can destabilize DIO3. When researchers disrupted the DIO3-SNXs colocalization, they observed a significant drop in cell proliferation and survival. Interestingly, this impairment specifically affected cells that overexpressed DIO3. Therefore, targeting the sorting nexin-associated routing offers a novel therapeutic strategy for ovarian cancer. This finding opens doors for precision medicine approaches in patients where high DIO3 expression drives disease aggressiveness.

FAQs

How does DIO3 contribute to ovarian cancer progression?

DIO3 inactivates thyroid hormones like T3, which are natural tumor suppressors. By reducing the local availability of these hormones, DIO3 promotes metabolic reprogramming and rapid cell proliferation in high-grade serous ovarian cancer.

What is the function of SNX2 and SNX6 in this context?

SNX2 and SNX6 act as the primary navigators for DIO3. SNX6 moves the enzyme through internal compartments like the Golgi, while SNX2 recycles it back to the cell surface, ensuring the enzyme stays active and stable.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional opinion. Always seek the direct advice of your physician or other qualified health care professional with any questions you may have regarding a medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Maman-Shinar D et al. DIO3 associates with sorting nexins and endosomal trafficking networks in ovarian cancer. Cell Oncol (Dordr). 2026 Jun 02. doi: 10.1007/s13402-026-01236-z. PMID: 42231032.

Ashur-Fabian O et al. DIO3 depletion attenuates ovarian cancer growth via reduced glycolysis and alterations in glutamine metabolism. Mol Metab. 2025. doi: 10.1016/j.molmet.2025.102225.

Cullen PJ, Korswagen HC. Sorting nexins provide diversity for retromer-dependent trafficking events. Nat Rev Mol Cell Biol. 2012;13(3):196-203.